Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2024-03-18 Earnings Release
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
Earnings Release Classification · 100% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces positive results from a Phase II clinical trial (LEGEND) for a drug candidate (lanifibranor). It details efficacy and safety data, includes quotes from management and investigators, and explicitly states that the company will host an investor webcast/conference call to discuss these results. This format—a formal announcement of significant corporate/clinical news, often released before a detailed presentation or filing—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing clinical trial results and providing key financial/clinical highlights, it fits best as an Earnings Release (ER) which often encompasses major operational updates, or potentially a Regulatory Filing (RNS) if it were less focused on immediate financial/trial results. Given the focus on announcing trial results and scheduling a call to discuss them, ER is a strong candidate, but since it is not explicitly an earnings report for a fiscal period, and it is a general announcement of material information, RNS (Regulatory Filings/General Announcement) is often the most appropriate catch-all for non-standard regulatory disclosures like clinical trial updates released via press release. However, many companies use ER for major clinical updates that precede formal scientific publications. Given the structure (key bullet points, detailed data tables, announcement of a webcast), it functions as a primary announcement of material information. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a clinical result announcement, RNS is the safer fallback for a material, non-standard filing. Let's re-evaluate: It is a press release announcing clinical data and scheduling a call. This is a material event disclosure. If it were a full report, it would be different. Since it's a press release announcing results and scheduling a follow-up call, it strongly resembles an Earnings Release structure (announcing results and scheduling a call), even if the results are clinical rather than purely financial. However, RNS is the general regulatory announcement category. Given the options, and the nature of clinical trial updates being material disclosures, RNS is the most accurate fit for a press release announcing trial data that isn't a standard quarterly financial report. FY 2024
2024-03-18 English
Franchissement de seuil
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuil (article L. 233-7 du code de commerce)" and details a change in significant share ownership (UBS Group AG crossing the 5% threshold of INVENTIVA's capital). This directly corresponds to the definition of a Major Shareholding Notification, which involves reporting changes in significant ownership levels crossing regulatory thresholds. The filing code for this is MRQ.
2024-03-14 French
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
Earnings Release Classification · 95% confidence The document is titled '# PRESS RELEASE' and announces that Inventiva will present results from a clinical trial (LEGEND Phase IIa) during an 'investor conference' on a specific date. It provides details for a conference call/webcast, followed by a Q&A session. The content focuses on communicating upcoming results and providing context about the drug candidate (lanifibranor) and the company. This structure—an announcement about presenting data via a call/webcast—is characteristic of an Earnings Release (ER) or a general announcement related to investor relations. Since it is announcing the presentation of clinical trial results rather than being the full transcript (CT) or a formal financial report (10-K/IR), and it is a formal press release format, it aligns best with an Earnings Release (ER) which often includes key operational/clinical updates alongside financial highlights, or an Investor Presentation (IP) announcement. Given the focus on presenting trial results via a conference call, ER is the most appropriate fit for a clinical-stage company's results announcement, even if the results themselves are clinical rather than purely financial earnings. The document is a press release announcing an event where data will be shared, which is a common format for ERs. Q1 2024
2024-03-13 English
Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2
Report Publication Announcement Classification · 95% confidence The document is a press release announcing that Inventiva will hold an investor conference call/webcast on March 19, 2024, to present the results of its Phase IIa LEGEND clinical study combining lanifibranor and empagliflozin. The text details the study, the drug (lanifibranor), and provides contact information. Crucially, it is an announcement *about* an upcoming presentation of data, not the presentation itself, nor is it a full financial report (10-K, IR) or a transcript of the call (CT). Since it announces the publication/presentation of information and provides webcast details, it fits best under 'Report Publication Announcement' (RPA), as it signals the release of clinical data/results via a conference call. If RPA were not available, 'Regulatory Filings' (RNS) would be the fallback, but RPA is more specific for announcements about the release of reports/data presentations.
2024-03-13 French
Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH
Legal Proceedings Report Classification · 99% confidence The document is titled as an announcement ("Inventiva annonce la reprise du *screening*...") and is structured like a press release, detailing an operational update regarding a clinical trial (NATiV3) for a drug candidate (lanifibranor). It discusses the resumption of patient screening/randomization following a voluntary pause due to a SUSAR and subsequent IRB approval. This type of communication, focusing on clinical trial progress, regulatory interactions (IRB/DMC), and operational milestones, is characteristic of an announcement intended for investors and the public, but it is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a specific financial event like an earnings release (ER) or dividend notice (DIV). Since it is a specific operational update that doesn't fit the other specialized categories (like M&A, Director's Dealing, or Capital Change), it falls best under the general category for regulatory/corporate announcements that are not otherwise specified, which is Regulatory Filings (RNS). It is not an Investor Presentation (IP) as it lacks the typical slide deck format, nor is it a Management Discussion & Analysis (MDA) which usually accompanies formal financial reports.
2024-03-07 French
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
Regulatory Filings Classification · 100% confidence The document is explicitly titled '# PRESS RELEASE' and begins with a headline announcing a clinical trial update ('Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed'). It details operational updates regarding a clinical trial (pausing/resuming screening, IRB approvals, patient enrollment targets, expected results timeline) and includes standard sections like 'About lanifibranor', 'About the NATiV3 Phase III trial', and 'Contacts'. This structure is characteristic of an Earnings Release (ER) or a general press release announcing significant operational news. Since it focuses on operational/clinical milestones rather than just summarizing quarterly financial figures (which would lean towards ER), and it is a formal announcement of company news, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS) if it were purely operational. However, given the detailed nature of the clinical update and the presence of the 'PRESS RELEASE' header, it functions as an announcement of material, non-financial operational news. In the context of the provided definitions, this type of announcement, which is a formal communication to the market about a significant operational event (clinical trial status), is often categorized as an Earnings Release (ER) if it accompanies financial results, or sometimes as a Regulatory Filing (RNS). Since it is a detailed update on a Phase III trial, it is more substantial than a simple 'RNS' announcement, but it is not a full financial report (10-K, IR) or a management discussion (MDA). Given the context of biopharma updates, these detailed operational press releases often fall under the 'ER' umbrella when they are the primary communication vehicle for the period's news, or RNS as a general regulatory announcement. Since it is a formal press release announcing a major operational update (resumption of screening after a pause), and it is not a transcript (CT), presentation (IP), or a specific financial report, 'ER' (Earnings Release, often used broadly for major operational announcements) or 'RNS' (Regulatory Filings) are the closest fits. Given the content is purely operational/clinical news, 'RNS' is the most appropriate fallback for a non-financial, material announcement not covered elsewhere. However, many companies issue these types of press releases concurrently with or instead of a formal ER. I will classify it as RNS as it is a general regulatory announcement about clinical operations, which is the broadest fit for non-specific material news.
2024-03-07 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.